Terms: = Endocrine gland cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1
49 results:
1. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract] [Full Text] [Related]
2. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
[TBL] [Abstract] [Full Text] [Related]
3. mkk4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract] [Full Text] [Related]
4. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
Jiang Y; Song L; Lin Y; Nowialis P; Gao Q; Li T; Li B; Mao X; Song Q; Xing C; Zheng G; Huang S; Jin L
Oncogene; 2023 May; 42(20):1672-1684. PubMed ID: 37020040
[TBL] [Abstract] [Full Text] [Related]
5. In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Chang CD; Chao MW; Lee HY; Liu YT; Tu HJ; Lien ST; Lin TE; Sung TY; Yen SC; Huang SH; Hsu KC; Pan SL
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166039. PubMed ID: 36683274
[TBL] [Abstract] [Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade.
Chiti G; Grazzini G; Flammia F; Matteuzzi B; Tortoli P; Bettarini S; Pasqualini E; Granata V; Busoni S; Messserini L; Pradella S; Massi D; Miele V
Radiol Med; 2022 Sep; 127(9):928-938. PubMed ID: 35917099
[TBL] [Abstract] [Full Text] [Related]
7. Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division.
Cedeno-Rosario L; Honda D; Sunderland AM; Lewandowski MD; Taylor WR; Chadee DN
J Biol Chem; 2022 Aug; 298(8):102263. PubMed ID: 35843311
[TBL] [Abstract] [Full Text] [Related]
8. ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via mek4/MAPK pathway.
Cai L; Wu ZR; Cao L; Xu JD; Lu JL; Wang CD; Jin JH; Wu ZB; Su ZP
Acta Pharmacol Sin; 2022 Sep; 43(9):2386-2396. PubMed ID: 35082393
[TBL] [Abstract] [Full Text] [Related]
9. A new prognosis prediction model combining TNM stage with map2k4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract] [Full Text] [Related]
10. microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
Sun Y; Zhang L; Zhang S
Cell Biochem Funct; 2020 Dec; 38(8):1017-1024. PubMed ID: 32495394
[TBL] [Abstract] [Full Text] [Related]
11. Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.
Zhang B; Meng M; Xiang S; Cao Z; Xu X; Zhao Z; Zhang T; Chen B; Yang P; Li Y; Zhou Q
Biochem Pharmacol; 2019 Aug; 166():70-81. PubMed ID: 31075266
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological and prognostic significance of mkk4 and MKK7 in resectable pancreatic ductal adenocarcinoma.
Lu J; Zhou L; Yang G; Liang ZY; Zhou WX; You L; Yuan D; Li BQ; Guo JC; Zhao YP
Hum Pathol; 2019 Apr; 86():143-154. PubMed ID: 30537492
[TBL] [Abstract] [Full Text] [Related]
13. MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.
Kleemann M; Schneider H; Unger K; Sander P; Schneider EM; Fischer-Posovszky P; Handrick R; Otte K
Sci Rep; 2018 Jun; 8(1):9020. PubMed ID: 29899543
[TBL] [Abstract] [Full Text] [Related]
14. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Genovese G; Carugo A; Tepper J; Robinson FS; Li L; Svelto M; Nezi L; Corti D; Minelli R; Pettazzoni P; Gutschner T; Wu CC; Seth S; Akdemir KC; Leo E; Amin S; Molin MD; Ying H; Kwong LN; Colla S; Takahashi K; Ghosh P; Giuliani V; Muller F; Dey P; Jiang S; Garvey J; Liu CG; Zhang J; Heffernan TP; Toniatti C; Fleming JB; Goggins MG; Wood LD; Sgambato A; Agaimy A; Maitra A; Roberts CW; Wang H; Viale A; DePinho RA; Draetta GF; Chin L
Nature; 2017 Feb; 542(7641):362-366. PubMed ID: 28178232
[TBL] [Abstract] [Full Text] [Related]
15. Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.
Aherne ST; Smyth P; Freeley M; Smith L; Spillane C; O'Leary J; Sheils O
Int J Mol Med; 2016 Aug; 38(2):433-45. PubMed ID: 27353001
[TBL] [Abstract] [Full Text] [Related]
16. LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and map2k4.
Liu J; Xu D; Wang Q; Zheng D; Jiang X; Xu L
Dig Dis Sci; 2014 Jul; 59(7):1452-60. PubMed ID: 24532253
[TBL] [Abstract] [Full Text] [Related]
17. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1.
Wang P; Chen L; Zhang J; Chen H; Fan J; Wang K; Luo J; Chen Z; Meng Z; Liu L
Oncogene; 2014 Jan; 33(4):514-24. PubMed ID: 23334332
[TBL] [Abstract] [Full Text] [Related]
18. Identification of common variants in BRCA2 and map2k4 for susceptibility to sporadic pancreatic cancer.
Huang L; Wu C; Yu D; Wang C; Che X; Miao X; Zhai K; Chang J; Jiang G; Yang X; Cao G; Hu Z; Zhou Y; Zuo C; Wang C; Zhang X; Zhou Y; Yu X; Dai W; Li Z; Shen H; Liu L; Chen Y; Zhang S; Wang X; Liu Y; Sun M; Cao W; Gao J; Ma Y; Zheng X; Cheung ST; Jia Y; Tan W; Wu T; Lin D
Carcinogenesis; 2013 May; 34(5):1001-5. PubMed ID: 23299404
[TBL] [Abstract] [Full Text] [Related]
19. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
Biankin AV; Waddell N; Kassahn KS; Gingras MC; Muthuswamy LB; Johns AL; Miller DK; Wilson PJ; Patch AM; Wu J; Chang DK; Cowley MJ; Gardiner BB; Song S; Harliwong I; Idrisoglu S; Nourse C; Nourbakhsh E; Manning S; Wani S; Gongora M; Pajic M; Scarlett CJ; Gill AJ; Pinho AV; Rooman I; Anderson M; Holmes O; Leonard C; Taylor D; Wood S; Xu Q; Nones K; Fink JL; Christ A; Bruxner T; Cloonan N; Kolle G; Newell F; Pinese M; Mead RS; Humphris JL; Kaplan W; Jones MD; Colvin EK; Nagrial AM; Humphrey ES; Chou A; Chin VT; Chantrill LA; Mawson A; Samra JS; Kench JG; Lovell JA; Daly RJ; Merrett ND; Toon C; Epari K; Nguyen NQ; Barbour A; Zeps N; ; Kakkar N; Zhao F; Wu YQ; Wang M; Muzny DM; Fisher WE; Brunicardi FC; Hodges SE; Reid JG; Drummond J; Chang K; Han Y; Lewis LR; Dinh H; Buhay CJ; Beck T; Timms L; Sam M; Begley K; Brown A; Pai D; Panchal A; Buchner N; De Borja R; Denroche RE; Yung CK; Serra S; Onetto N; Mukhopadhyay D; Tsao MS; Shaw PA; Petersen GM; Gallinger S; Hruban RH; Maitra A; Iacobuzio-Donahue CA; Schulick RD; Wolfgang CL; Morgan RA; Lawlor RT; Capelli P; Corbo V; Scardoni M; Tortora G; Tempero MA; Mann KM; Jenkins NA; Perez-Mancera PA; Adams DJ; Largaespada DA; Wessels LF; Rust AG; Stein LD; Tuveson DA; Copeland NG; Musgrove EA; Scarpa A; Eshleman JR; Hudson TJ; Sutherland RL; Wheeler DA; Pearson JV; McPherson JD; Gibbs RA; Grimmond SM
Nature; 2012 Nov; 491(7424):399-405. PubMed ID: 23103869
[TBL] [Abstract] [Full Text] [Related]
20. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract] [Full Text] [Related]
[Next]
